TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19060628
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg immediate-release fluvastatin twice daily (b.i.d.)
Study: 19060628
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg extended-release fluvastatin daily
Study: 18090187
Drug: Premedication with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedication with diazepam 5-10 mg
Study: 15144039
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (group A)
Study: 15144039
Drug: Influenza and
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza and pneumococcus vaccines simultaneously (group B)
Study: 11228086
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate aerosol (1.25 mg upon arrival and a second dose 15 minutes later if needed)
Study: 11228086
Drug: Sublingual isosorbide
Normalized name: isosorbide dinitrate Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isosorbide dinitrate (5 mg tablet)
Study: 9972670
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of methimazole (MMI) and 20 g of colestipol‐hydrochloride (COL) daily
Study: 9972670
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of MMI daily
Study: 9972670
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of MMI and 20 g of COL daily
Study: 8054260
Drug: Magnesium pidolate
Normalized name: magnesium pidolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium pidolate 4.5 g/d for one month
Study: 3175536
Drug: Acarbose (Bay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (Bay g 5421)
Study: 26698878
Drug: Ibuprofen 3
Normalized name: ibuprofen 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 3 × 400 mg for three days
Study: 26698878
Drug: Fosfomycin 3
Normalized name: fosfomycin 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin 3 g (single dose) for three days
Study: 17201265
Drug: Xuanju compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuanju compound capsule combined with erogenous focus exercise
Study: 8446138
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 to 360 mg per day)
Study: 8446138
Drug: Atenolol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (25 to 100 mg per day)
Study: 8446138
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 to 0.6 mg per day)
Study: 8446138
Drug: Hydrochlorothiazide (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (12.5 to 50 mg per day)
Study: 8446138
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 to 100 mg per day)
Study: 8446138
Drug: Prazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (4 to 20 mg per day)
Study: 25792588
Drug: Gel pad
Normalized name: Zenphor Gel Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel pad application
Study: 25792588
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel pad application (control)
Study: 18633420
Drug: Motor physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor physical therapy (15 min daily, 5 times per week until discharge)
Study: 12770975
Drug: topical dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical dorzolamide
Study: 9601864
Drug: Spirapril 3
Normalized name: spirapril 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 3 mg or 6 mg
Study: 9601864
Drug: Spirapril 12
Normalized name: spirapril 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 12 mg (small proportion of patients)
Study: 9601864
Drug: Spirapril (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril (overall treatment)
Study: 8224265
Drug: Flutamide 750
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 750 mg/d
Study: 8224265
Drug: Flutamide 500
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 500 mg/d and 750 mg/d
Study: 29120250
Drug: Nepafenac treatment
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nepafenac treatment (0.1%, three times/day)
Study: 26642810
Drug: Lapatinib (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1250 mg) combined with Capecitabine (2000 mg/m2 on days 1 to 14)
Study: 26642810
Drug: Lapatinib (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1250 mg) combined with Vinorelbine (25 mg/m2 on days 1 and 8)
Study: 26642810
Drug: Lapatinib (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1250 mg) combined with Gemcitabine (1000 mg/m2 on days 1 and 8)
Study: 24690511
Drug: Group-based self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based self-management support programme (three monthly group sessions and a booster session three months later)
Study: 23220811
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1500 mg/day) plus exercise therapy
Study: 18591457
Drug: Valsartan (low-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (low-, medium-, or high-dose)
Study: 11295408
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g fosfomycin trometamol (single-dose)
Study: 11295408
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg ceftibuten (3-day course)
Study: 7970503
Drug: Cyclical, sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical, sequential combination of tamoxifen and megestrol acetate (group B)
Study: 28787507
Drug: Levosimendan (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.1 µg/kg/min for 24 hours)
Study: 26978493
Drug: D‐, L‐hopantenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: D‐, L‐hopantenic acid (pantogam active) at a daily dose of 600 to 1200 mg for 28 days
Study: 26978493
Drug: Standard cardiotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cardiotropic hypotensive treatment (Control)
Study: 24139424
Drug: Delayed-release dimethyl
Normalized name: dimethyl fumarate Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release dimethyl fumarate (DR-DMF)
Study: 24139424
Drug: Delayed-release dimethyl
Normalized name: dimethyl fumarate Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release dimethyl fumarate (DR-DMF) with aspirin pretreatment
Study: 20878292
Drug: Behavioral weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral weight loss treatment
Study: 14618246
Drug: HYPER‐HES (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYPER‐HES (150 ml/m2 hypertonic NaCl (7.2%) 10% HES 200/0.5)
Study: 14618246
Drug: HYPER‐DEX (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYPER‐DEX (150 ml/m2 hypertonic NaCl (7.2%) 10% dextran 60)
Study: 14618246
Drug: HES (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES (250 ml/m2 10% HES 200/0.5 plus 400 ml/m2 NaCl 0.9%)
Study: 14618246
Drug: DEX (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (250 ml/m2 10% dextran 40 plus 300 ml/m2 NaCl 0.9%)
Study: 14618246
Drug: NACL (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACL (750 ml/m2 NaCl 0.9%)
Study: 8694323
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL bupivacaine 0.5% (Group 1)
Study: 8694323
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL saline (Group 2)
Study: 31770235
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin D treatment
Study: 31770235
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficiency (not receiving treatment)
Study: 27603001
Drug: Prolotherapy (intra-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy (intra- and extra-articular hypertonic dextrose injection)
Study: 25132212
Drug: Alogliptin 12.5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg once daily (n = 880)
Study: 25132212
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg once daily (n = 885)
Study: 25132212
Drug: Glipizide 5
Normalized name: glipizide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 5 mg once daily, titrated to a maximum of 20 mg (n = 874)
Study: 22243959
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (mean 40.6 mg, SD 25 mg)
Study: 22243959
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine alone (mean 14.4 mg, SD 9.4 mg)
Study: 22243959
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of ketamine and morphine
Study: 19858761
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (COMB) with risperidone and parent training (PT)
Study: 19858761
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (MED)
Study: 18281620
Drug: Multilevel botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multilevel botulinum toxin A injections
Study: 16168278
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 100 mg/day administered before bedtime
Study: 16168278
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 100 mg/day administered on awakening
Study: 12514662
Drug: Ineligible patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ineligible patients not treated with reperfusion therapy (Control)
Study: 8683232
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide phosphate (EP) at 125 mg/m2/d for 5 days
Study: 8683232
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide phosphate (EP) at 150 mg/m2/d for 5 days
Study: 8683232
Drug: Intravenous etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous etoposide (E) at 80 mg/m2 for 1 hour
Study: 8683232
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide phosphate (EP)
Study: 2054272
Drug: Propranolol (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (repeated administration)
Study: 2054272
Drug: Verapamil and
Normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil and Propranolol (co-administered as single doses)
Study: 2054272
Drug: Propranolol (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (repeated doses)
Study: 2054272
Drug: Verapamil and
Normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil and Propranolol (single and repeated oral doses in combination)
Study: 2054272
Drug: Verapamil and
Normalized name: trandolapril and verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil and Propranolol (single doses in combination)
Study: 30716803
Drug: Post-auricular subperiosteal
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-auricular subperiosteal injection of methylprednisolone combined with ginkgo biloba injection and mouse nerve growth factor
Study: 30716803
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba injection and mouse nerve growth factor
Study: 25245975
Drug: 30-min postload
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-min postload glucose ≥ 165 mg/dL and 30-min C-peptide < 5 ng/mL
Study: 7537664
Drug: Casodex 50
Normalized name: Casodex 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 50 mg/day
Study: 7537664
Drug: Casodex 50
Normalized name: Casodex 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 50 mg/day for prostate cancer
Study: 7537664
Drug: Casodex 50
Normalized name: Casodex 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 50 mg/day for benign prostatic hyperplasia (BPH)
Study: 7537664
Drug: Casodex (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (various doses)
Study: 2686666
Drug: Supervised outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised outpatient physical therapy
Study: 18070967
Drug: APL 600
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 600 mg BID
Study: 18070967
Drug: APL 800
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 800 mg BID
Study: 18070967
Drug: APL 200
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 200 mg BID
Study: 18070967
Drug: APL 400
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 400 mg BID
Study: 18070967
Drug: APL 800
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL 800 mg once a day
Study: 17126779
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin (5 mL/kg)
Study: 17126779
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (25 mL/kg)
Study: 14566178
Drug: Low iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low iodine concentration (300 mg/mL) at slow flow rate (2.5 mL/s)
Study: 14566178
Drug: Low contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low contrast concentration (300 mg/mL) at high flow rate (3.5 mL/s)
Study: 14566178
Drug: High contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: High contrast concentration (400 mg/mL) at high flow rate (3.5 mL/s)
Study: 14566178
Drug: Approximately 1
Normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1 g iodine/s
Study: 8900980
Drug: Hypovolemic condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypovolemic condition (induced by 30 mg furosemide)
Study: 2049253
Drug: PGE1 (Prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (Prostaglandin E1) infused at doses ranging from 0.01 to 1.3 micrograms kg‐1 min‐1
Study: 2049253
Drug: Control saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control saline solution (isotonic)
Study: 30412032
Drug: HYP-CHO (carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYP-CHO (carbohydrate solution in hypoxia)
Study: 18495372
Drug: High-tech external
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-tech external beam therapy (EBT)
Study: 12656706
Drug: Web-based self-help
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based self-help program with e-mail support + weekly individual telephone calls
Study: 11023140
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (goal HbA(1c) 7.1%)
Study: 11023140
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (goal HbA(1c) 9.1%)
Study: 9083166
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (124 +/- 22 mg per day)
Study: 9083166
Drug: Controlled-release hydromorphone
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release hydromorphone (30 +/- 6 mg per day)
Study: 3789915
Drug: High-dose doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose doxorubicin therapy
Study: 3789915
Drug: Low-dose doxorubicin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxorubicin therapy
Study: 30075780
Drug: Interactive power
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interactive power toothbrush (IPT) - Oral-B® ProfessionalCare 6000 with Bluetooth
Study: 30075780
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (MT) - Oral-B® Indicator soft manual toothbrush
Study: 24780850
Drug: Intradiskal methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiskal methylene blue injection
Study: 18334911
Drug: Iloperidone 12
Normalized name: iloperidone 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone 12 mg/d
Study: 18334911
Drug: Iloperidone 4-8
Normalized name: iloperidone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone 4-8 mg/d
Study: 18334911
Drug: Iloperidone 10-16
Normalized name: iloperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone 10-16 mg/d
Study: 18334911
Drug: Iloperidone 20-24
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 20-24 mg/d
Study: 18334911
Drug: Risperidone 4-8
Normalized name: risperidone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 4-8 mg/d
Study: 8723448
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G (3 g every 6 hours)
Study: 8723448
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg every 24 hours)
Study: 1328358
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (5-10 mg norethynodrel with mestranol 0.075-0.15 mg or conjugated estrogens 0.625 mg)
Study: 3526804
Drug: Tinidazole 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole 1,600 mg i.v. preoperatively
Study: 26983925
Drug: Lidocaine cream
Normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine cream applied from wrist to shoulder
Study: 26983925
Drug: Neutral cream
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral cream (placebo) applied to the same skin area
Study: 26983925
Drug: Neutral cream
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral cream (placebo)
Study: 24106340
Drug: Active doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active doxycycline (100 mg BID for 7 days)
Study: 21880289
Drug: High on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High on-treatment platelet reactivity (HOPR) defined as OPR ≥235 P2Y12 reactivity units
Study: 21880289
Drug: Normal on-treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal on-treatment platelet reactivity (non-HOPR)
Study: 8005278
Drug: i.v. administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration of 50 g of human albumin diluted in 500 mL of sodium chloride 0.9%
Study: 8005278
Drug: sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium chloride 0.9% solution
Study: 2686741
Drug: Cefadroxil 1
Normalized name: CEFADROXIL 1GM TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1 g twice daily
Study: 2686741
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg three times a day
Study: 12454840
Drug: Entecavir 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.1 mg/day
Study: 12454840
Drug: Entecavir 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.1 mg/day and 0.5 mg/day
Study: 27659102
Drug: Self-referral to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-referral to inpatient treatment (contract for self-referral, maximum 5 days, quarantine time of 14 days between stays)
Study: 24797321
Drug: ADH1B*2/*2 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADH1B*2/*2 group with 0.25 g/kg EtOH
Study: 24797321
Drug: ADH1B*2/*2 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADH1B*2/*2 group with 0.5 g/kg EtOH
Study: 24797321
Drug: ADH1B*1/*2 group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADH1B*1/*2 group at 0.5 g/kg EtOH
Study: 22928903
Drug: Early dental
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early dental treatment for severe dental caries
Study: 22928903
Drug: Control (regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (regular dental treatment)
Study: 20361072
Drug: SCM‐III symbiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCM‐III symbiotic mixture, 10 ml three times a day
Study: 10210074
Drug: Semitendinosus and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semitendinosus and gracilis (ST/G)
Study: 7610222
Drug: Social support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social support therapy
Study: 2379533
Drug: Furegrelate 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furegrelate 800 mg
Study: 2379533
Drug: Furegrelate 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furegrelate 1600 mg
Study: 2379533
Drug: Furegrelate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furegrelate (all doses)
Study: 2379533
Drug: Furegrelate (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furegrelate (higher doses)